The role of basket trials in small cancer subsets will be important to defining what targeted therapies work well...
Oncolytic viruses are fast becoming a hot new area in cancer research but who are the players and where is this field going?
Exploring NY-ESO-1 as a valid target in sarcoma, multiple myeloma and metastatic melanoma...
Will checkpoint inhibitors make their mark in renal cell carcinoma and how will they be integrated into a treatment paradigm dominated by VEGF inhibitors?
This month's Biotech Strategy Blog mail bag.
Interview with Dr Rob Iannone of AstraZeneca on their IO pipeline
Clovis have started their rolling NDA for rociletinib in T790M-positive lung cancer - what about AstraZeneca's AZD9291?
Interview with Dr William Pao on the Roche antibody based cancer immunotherapy strategy.
ASCO 2015 interview with Dr James Gulley from NCI on Prostate Cancer Immunotherapy.
What's hot in soft tissue sarcomas at ASCO 2015? Find out more...
Insights on targeted therapies from ASCO - questions from subs on neratinib, bavituximab, enzalutamide, Gilead's pipeline and MDSCs...
We've heard a lot about checkpoint immunotherapies in non-small cell lung cancer (NSCLC), but what about it's deadlier cousin, small cell lung cancer (SCLC)? Find out more...
Beyond the Big Four in checkpoint inhibitors, there is a raft of other companies anxious to get in the action. We take a look at Merck Serono and their progress with avelumab, an anti-PDL1 antibody
How do we help patients who are non-responders or have stable disease respond to checkpoint inhibitors? Will chemotherapy combos help or not?
Highlights from Monday at the 2015 ASCO annual meeting in Chicago
What's hot on Plenary Sunday at ASCO 2015? We'll be updating this blog post during the day.
Highlights from Day 2 at ASCO 15 in Chicago
Reflections on data presented in the first cancer immunotherapy press briefing at ASCO 2015
Do you need to incorporate a suicide suicide switch into CAR T cells that allows you to turn off the response, force the T cells to self-destruct?
Targeting MYC and bromodomains is an emerging area of research as we learn more about super enhancer transcription factor clusters around oncogenes that drive cancer.
Data at ASGCT and ASCO highlight potential new treatments in development for multiple myeloma
First in a series of previews of ASCO 2015 annual meeting abstracts.
What are the hot checkpoint studies to watch out for at ASCO 2015? We created a cheat sheet to follow and track the data as tsunami hits...
